Bacillus Calmette-Guérin immunotherapy in ovarian cancer.
Forty-six advanced ovarian cancer patients treated with conventional modalities with the addition of bacillus Calmette-Guérin (BCG) immunotherapy showed prolonged survival when compared to controls not given BCG. Although the data suggest enhancement of survival with the addition of BCG to conventional treatment, the fact remains that disease recurrence ultimately claims the lives of most of these patients. Nonetheless, patients are surviving longer in the face of advanced disease.
Pattillo
R A
RA
Department of Gynecology and Obstetrics, Medical College of Wisconsin, Milwaukee.
Komaki
R
R
Reynolds
M
M
Robles
J
J
D001500:BCG Vaccine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine